Pretreatment doses of antithymocyte globubin-fresenius for allogeneic hematopoietic stem cell transplantation for beta-thalassemia major.
- Author:
Chunfu LI
1
;
Yanhua WANG
;
Xuedong WU
;
Fuyu PEI
;
Yuelin HE
;
Xiaoqin FENG
;
Huaying LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Animals; Antilymphocyte Serum; administration & dosage; immunology; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; methods; Humans; Lymphocytes; immunology; Male; Rabbits; Transplantation Conditioning; methods; beta-Thalassemia; immunology; surgery
- From: Journal of Southern Medical University 2012;32(5):691-694
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effects of different doses of antithymocyte globubin-fresenius (ATG-F) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with beta-thalassemia Major.
METHODSSixty-four children with beta-thalassemia major undergoing allo-HSCT were divided into two equal groups to receive ATG-F pretreatments at high (30 mg/kg) or low (15 mg/kg) doses as part of the conditioning regimen including mainly cyclophosphamide, busulfan, fludarabine, and thiotepa. The outcomes of the patients were compared between the two groups.
RESULTSNo obvious difference were noted in the time to leukocyte and platelet engraftment between the two groups. The incidence of grade II-IV acute graft-versus-host disease (aGVHD) appeared to be higher in the low-dose group than in the high-dose group (12.5% vs 9.4%). The incidence of grade III-IV aGVHD was also higher in the low dose group (12.5% vs 6.3%), but the difference was not statistically significant. Application of high-dose ATG-F was associated with a higher rate of probable and possible fungal infection (P<0.05).
CONCLUSIONThe two doses of ATG-F is feasible as a part of the conditioning regimen for allo-HSCT in children with beta-thalassemia major.
